Future oncology
-
Review Meta Analysis
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
We performed a meta-analysis of the risk of cutaneous toxicities associated with immune checkpoint inhibitors. ⋯ Our meta-analysis demonstrates that immune checkpoint inhibitors are associated with an increased risk of all grade skin rash, vitiligo and pruritus. Clinicians should perform regular clinical cutaneous monitoring.
-
Meta Analysis
Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.
Identify sensitive end points and populations for similarity studies of trastuzumab and biosimilar monoclonal antibodies. ⋯ Treatment of patients with neoadjuvant breast cancer represents a sensitive setting for establishing biosimilarity of efficacy and immunogenicity. tpCR is a sensitive end point in this setting to establish biosimilarity between a biosimilar candidate and its reference product.
-
Review Meta Analysis
Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
We performed a meta-analysis of the risk of hematological adverse events associated with ramucirumab. ⋯ Our meta-analysis has demonstrated an increased risk of febrile neutropenia, all-grade and high-grade neutropenia and thrombocytopenia with ramucirumab-based treatment compared with control.